Skip to content
fren

Biomechanical innovation

Give the pelvisback its freedomof movement.

A robotic seat that moves the pelvis and lower back, with no effort or alongside exercises. For rehabilitation, prevention, sport and healthy ageing.

Book a demonstrationSee the device
Randomised pilot study · Jessa Hospital
Lumbar spine and pelvis, guided by LumbaCure® movement trajectories
6 axes
Simultaneous multidimensional mobilisation
Passive · Active
Two ways to use it
Pilot study
Jessa Hospital, Belgium
10–15 min
Preventive programmes

01A unique technology

The user sits on the device. A programme guides the pelvis in several directions at once, with passive mobilisation or exercises adapted by the professional.

The LumbaCure® device: robotic seat, handles and footrests
LumbaCure® · a robotic seat with 6 degrees of freedom

The device creates the movement.

The user makes no voluntary effort. Once seated and the programme selected, the session can run without constant supervision, particularly in a preventive setting.

  1. 01

    Take a seat

    The user sits on the device.

  2. 02

    Choose the programme

    The professional adapts the mode and programme to the user’s profile and goal.

  3. 03

    Start the session

    The seat guides the movements. Preventive programmes usually last 10 to 15 minutes.

On video

LumbaCure® in motion

Filmed during a demonstration: the seat on its own, then with a user.

Empty: the seat guides the pelvis in several directions at once.
In a session: the user sits back and is mobilised.
Explore the 6 axes and device features
Lumbar spine and pelvis, guided by LumbaCure® movement trajectories

Six axes, controlled simultaneously

Rx
Flexion / extension
Ry
Lateral tilt
Rz
Axial rotation
Tx
Lateral translation
Ty
Vertical translation
Tz
Front-to-back translation

  • 6 simultaneous degrees of freedom

    Multidimensional mobilisation along programmed, progressive lumbo-pelvic trajectories.

  • Reproducible trajectories

    Standardised sessions suited to healthcare facilities, companies and sports settings.

  • Biomechanical precision

    Guided mobilisation with no forced manipulation, respecting neurophysiology.

  • Suits many profiles

    Suitable for a wide audience, including people with reduced mobility.

Three simultaneous actions

  1. Regain movement

    Rhythmic movements promote mechanical pumping in the lumbo-pelvic structures. Progressive trajectories support the return to movement in a programmed, reproducible way.

  2. Release tension

    Smooth movements help relax areas under daily strain, for a feeling of release and lightness.

  3. Support lumbo-pelvic mobility

    LumbaCure® guides the pelvis through all 6 degrees of freedom, enabling safe, reproducible proprioceptive reintegration of movement.

02Clinical study

A prospective, randomised, controlled pilot study run from June 2024 to June 2025. It observed trends favouring LumbaCure® on functional recovery, pain and pain catastrophising.

See the study in detail

How to read these results

Exploratory pilot study, not yet published in a peer-reviewed journal. The primary endpoint (change in ODI at visit 2) did not reach statistical significance: p = 0.101. These descriptive responder comparisons do not establish definitive efficacy.

Everyday function · visit 2ODI: functional disability. Relative improvement of at least 25%
LumbaCure®
LumbaCure®: 43.5%
Control
Control: 10%
Pain · visit 5Relative improvement of at least 25%
LumbaCure®
LumbaCure®: 77.8%
Control
Control: 37.5%
Pain catastrophising · visit 4PCS: negative thoughts about pain. Improvement of at least 7 points
LumbaCure®
LumbaCure®: 65%
Control
Control: 21.1%

V2, V4 and V5 refer to protocol visits 2, 4 and 5. Each threshold defines the improvement required to be counted as a responder.

Source: LumbaCure2302 clinical investigation report, version 1.2, 14/08/2025. Exploratory pilot study; results not yet published in a peer-reviewed journal.

03Applications

04A global public-health challenge

In 2020, around 619 million people were living with low back pain — nearly one person in thirteen. Its impact goes beyond pain: reduced function, loss of independence, absenteeism and lower quality of life make mobility a major public-health issue.

619 M
people were living with low back pain in 20201
843 M
people projected to be affected by 2050 — up 36% in three decades2
€2.4 bn
paid each year by French employers in contributions for musculoskeletal disorders and low back pain3
90%
of low back pain cases are not linked to a specific condition4
  1. 1. WHO, low back pain fact sheet, 2023 ↗
  2. 2. WHO, low back pain fact sheet, 2023 ↗
  3. 3. French National Health Insurance – Occupational Risks ↗
  4. 4. WHO, 2023 ↗

05Integration

  • Enhance your offer

    A distinctive technology for mobility, function and independence.

  • Streamline your organisation

    In passive mode, sessions can run without constant supervision once the programme starts.

  • Launch new programmes

    Rehabilitation, MSD prevention, mobility maintenance, recovery and sports performance.

  • Track and evaluate

    Reproducible trajectories make monitoring, evaluation and continuity easier.

Preserve mobility. Restore function. Sustain independence.

Book a demonstrationor get a call back